Vaccines

metrics 2024

Transforming immunization strategies with groundbreaking research.

Introduction

Vaccines, published by MDPI in Switzerland, is a leading open access journal that has been at the forefront of vaccine research since its inception in 2013. With an impressive impact factor and consistently ranked in the Q1 and Q2 quartiles across leading categories such as Drug Discovery, Immunology, Infectious Diseases, and Pharmacology, it provides a vital platform for researchers to share their findings and advance the field. The journal is dedicated to delivering high-quality original research articles, reviews, and case studies that address the challenges and innovations in vaccine development and immunization strategies worldwide. Open access since its launch, Vaccines ensures that cutting-edge research is widely available to the global academic community and public health professionals, thereby fostering collaboration and enhancing knowledge in this critical area of public health.

Metrics 2024

SCIMAGO Journal Rank-
Journal Impact Factor5.20
Journal Impact Factor (5 years)4.90
H-Index-
Journal IF Without Self5.20
Eigen Factor0.04
Normal Eigen Factor8.90
Influence1.05
Immediacy Index1.20
Cited Half Life2.20
Citing Half Life3.90
JCI1.23
Total Documents-
WOS Total Citations25994
SCIMAGO Total Citations-
SCIMAGO SELF Citations-
Scopus Journal Rank-
Cites / Document (2 Years)-
Cites / Document (3 Years)-
Cites / Document (4 Years)-

Metrics History

Rank 2024

IF (Web Of Science)

IMMUNOLOGY
Rank 45/181
Percentile 75.40
Quartile Q1
MEDICINE, RESEARCH & EXPERIMENTAL
Rank 39/189
Percentile 79.60
Quartile Q1

JCI (Web Of Science)

IMMUNOLOGY
Rank 33/181
Percentile 81.77
Quartile Q1
MEDICINE, RESEARCH & EXPERIMENTAL
Rank 36/189
Percentile 80.95
Quartile Q1

Quartile History

Similar Journals

npj Vaccines

Pioneering Discoveries in Immunization Strategies
Publisher: NATURE PORTFOLIOISSN: Frequency: 1 issue/year

npj Vaccines, published by NATURE PORTFOLIO, is an esteemed Open Access journal that has been at the forefront of vaccination research since its inception in 2016. With an impressive impact factor and ranking in the top quartile (Q1) across several categories including Immunology, Infectious Diseases, and Pharmacology, this journal provides a crucial platform for the dissemination of high-quality research and innovative findings in the field of vaccine development. Based in the United Kingdom, and with its broad scope encompassing both fundamental and translational studies, npj Vaccines facilitates significant discourse among researchers, professionals, and students dedicated to immunization strategies and public health. The journal's commitment to Open Access ensures that vital knowledge is shared widely, promoting collaboration and advancement in vaccine science on a global scale. Scholars are encouraged to contribute to this essential field, as their findings may significantly impact the future of disease prevention and control.

Tropical Diseases Travel Medicine and Vaccines

Connecting research and practice for a healthier tomorrow.
Publisher: SPRINGERNATUREISSN: 2055-0936Frequency: 1 issue/year

Tropical Diseases Travel Medicine and Vaccines, published by SPRINGERNATURE, stands at the forefront of research in the fields of infectious diseases and public health, with an impressive impact factor that signifies its relevance and influence. Since its inception in 2015, this peer-reviewed journal has maintained an open access policy, ensuring that cutting-edge research on tropical diseases and travel medicine is readily available to researchers, professionals, and students worldwide. The journal currently ranks in the Q2 Quartile for both Infectious Diseases and Public Health, Environmental and Occupational Health, reflecting its substantial contribution to these critical areas of study. With a strong Scopus rank of #176 in Public Health and #138 in Infectious Diseases, it serves as a vital platform for innovative studies that advance understanding and response strategies related to tropical diseases. For its vast audience, Tropical Diseases Travel Medicine and Vaccines not only acts as a bridge connecting researchers with practical applications but also nurtures academic discourse essential for future advancements in global health.

Infectious Agents and Cancer

Unraveling the complex interplay of infectious agents and oncology.
Publisher: BMCISSN: 1750-9378Frequency: 1 issue/year

Infectious Agents and Cancer is a pivotal open access journal published by BMC, dedicated to advancing research at the intersection of infectious diseases and oncology. Since its inception in 2006, this journal has provided a platform for the exploration of the complex relationships between infectious agents and cancer development, aimed at researchers, healthcare professionals, and students alike. With a broad scope encompassing epidemiology and cancer research, the journal holds an impressive ranking in the Q3 quadrant for epidemiology, infectious diseases, and oncology in 2023, while also featuring in the Q4 category for cancer research. This distinguished journal not only contributes to the enrichment of scientific knowledge but also fosters collaborative efforts towards innovative solutions in the fight against cancer. Being part of the UK publishing landscape, the journal is accessible to a global audience, ensuring that vital research findings are disseminated widely to inform policy and practice in health sciences.

BIOLOGICALS

Advancing the frontiers of biological research.
Publisher: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTDISSN: 1045-1056Frequency: 6 issues/year

BIOLOGICALS, published by Academic Press Ltd - Elsevier Science Ltd, is a prestigious journal dedicated to advancing the fields of applied microbiology, biotechnology, immunology, and pharmacology. With an ISSN of 1045-1056 and E-ISSN of 1095-8320, this journal has established itself as a vital resource for researchers and practitioners, offering rigorous peer-reviewed content that spans converging disciplines from 1990 to 2024. With a commendable presence in the field, it ranks in the Q3 category across multiple domains, including applied microbiology and biotechnology, highlighting its contribution to critical advancements and knowledge dissemination. The journal's rankings reflect its relevance, with notable placements in Scopus Ranks, ensuring it remains an important platform for innovative research and discussion. Although it does not currently offer Open Access, the journal’s comprehensive review process guarantees the quality of published work, making it essential reading for professionals, academics, and students seeking to stay informed about the latest developments in biology and life sciences.

Infectious Diseases

Connecting Scholars in the Battle Against Infectious Diseases
Publisher: TAYLOR & FRANCIS LTDISSN: 2374-4235Frequency: 12 issues/year

Infectious Diseases, published by TAYLOR & FRANCIS LTD, is a leading academic journal dedicated to advancing research in the field of infectious diseases and microbiology. With an impressive impact factor and categorized in Q1 in multiple areas including Immunology and Microbiology, this journal serves as a critical platform for researchers, practitioners, and students to disseminate their findings and stay abreast of current advancements. The journal is recognized for its rigorous peer-review process and aims to foster innovation and collaboration across disciplines from 2015 to 2024. It boasts a robust Scopus ranking, positioning it favorably among the top-tier of journals in the relevant fields, making it an essential resource for anyone involved in infectious disease research. Access options are available, ensuring that the latest research is accessible to a global audience, thus emphasizing the journal's commitment to promoting knowledge and understanding in the ever-evolving landscape of infectious diseases.

Emerging Microbes & Infections

Pioneering discoveries in microbial health.
Publisher: TAYLOR & FRANCIS LTDISSN: Frequency: 1 issue/year

Emerging Microbes & Infections is a premier open access journal, published by Taylor & Francis Ltd since 2012, dedicated to advancing the understanding of microbial infections and their implications in human health. With an impressive Q1 ranking across multiple categories—including Drug Discovery, Epidemiology, Immunology, and Infectious Diseases—this journal is at the forefront of research in the microbiological sciences. Covering a diverse range of topics, it serves as a vital resource for researchers, healthcare professionals, and students alike. The journal's commitment to open access ensures worldwide dissemination of cutting-edge findings, fostering collaboration and innovation in tackling challenges posed by emerging infections. As part of the thriving academic community in the United Kingdom, Emerging Microbes & Infections plays a crucial role in shaping the future of infectious disease research and public health.

Vaccine: X

Empowering global health through cutting-edge vaccine research.
Publisher: ELSEVIERISSN: 2590-1362Frequency:

Vaccine: X, published by Elsevier, is a premier open access journal dedicated to advancing research in the interdisciplinary fields of immunology and microbiology, infectious diseases, molecular medicine, and public health. With an ISSN of 2590-1362 and operating since 2019, the journal has rapidly established an influential role, achieving Q2 rankings in major categories such as Immunology and Microbiology, Infectious Diseases, and Public Health for 2023. Its commitment to disseminating cutting-edge research is evident from its broad scope, focusing on innovative vaccines and therapies that are critical for global health. Researchers and professionals will find value in the accessible nature of the journal, which has been recognized for its contributions to veterinary medicine as well, with a Q1 ranking in the miscellaneous veterinary category. The journal proudly showcases high-quality, peer-reviewed articles and welcomes submissions that push the boundaries of current knowledge, making it an essential resource for anyone involved in vaccine research and development.

Infektsiya i Immunitet

Advancing knowledge in immunology and infectious diseases.
Publisher: SANKT-PETERSBURG-NIIEM IMENI PASTERAISSN: 2220-7619Frequency: 4 issues/year

Infektsiya i Immunitet, published by the esteemed SANKT-PETERSBURG-NIIEM IMENI PASTERA, is a prominent open access journal that has been disseminating vital research findings since 2011. Focusing on the fields of immunology and infectious diseases, this journal serves as a critical platform for scholars, professionals, and students in the Russian Federation and beyond. With an ISSN of 2220-7619 and an E-ISSN of 2313-7398, it currently holds a Q4 ranking in 2023 for both Immunology and Infectious Diseases, along with notable quartile standings in related fields. Despite its emerging status, Infektsiya i Immunitet provides valuable insights and contributes to the growing discourse on immunity and infection prevention strategies, making it an essential resource for those invested in advancing knowledge and enhancing public health outcomes. Researchers can conveniently access its wealth of articles and studies that bridge theoretical understanding and practical implications in their respective domains.

Future Science OA

Connecting researchers to shape tomorrow's science.
Publisher: FUTURE SCI LTDISSN: 2056-5623Frequency: 10 issues/year

Future Science OA is an esteemed open-access journal published by FUTURE SCI LTD, dedicated to advancing knowledge in the fields of biotechnology and medicine. Established in 2015, this journal has rapidly gained recognition within the scientific community, evidenced by its impressive ranking in both General Medicine (Rank #100/636, 84th percentile) and Biotechnology (Rank #145/311, 53rd percentile) as per Scopus metrics. With a Q2 category quartile in both fields as of 2023, Future Science OA provides a vital platform for researchers, professionals, and students to share groundbreaking research and innovative ideas. Notably, being an open-access journal allows for a wider dissemination of knowledge, ensuring equal access to high-quality research for practitioners and scholars alike. Based in the United Kingdom, Future Science OA is committed to fostering collaboration and dialogue within the scientific community, making it a cornerstone resource for advancing the future of the life sciences.

EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE

Pioneering Studies in Microbiology and Public Health
Publisher: CESKA LEKARSKA SPOLECNOST J EV PURKYNEISSN: 1210-7913Frequency: 4 issues/year

EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE is a prominent scholarly journal published by CESKA LEKARSKA SPOLECNOST J EV PURKYNE in the Czech Republic. With an ISSN of 1210-7913, this journal has been at the forefront of research since its inception in 1994, showcasing a rich repository of studies bridging the domains of epidemiology, microbiology, immunology, and infectious diseases, and reflecting advancements over three decades. Although it currently falls within the Q4 category in multiple fields including Epidemiology and Microbiology, the journal serves an essential role in disseminating knowledge and fostering discussions around public health challenges. The contributions made through its pages are vital for researchers, healthcare professionals, and students aiming to enhance their understanding of complex biomedical issues. While it does not offer open access, the journal remains a critical resource in its niches, inviting readers to engage with the latest findings and methodologies reshaping the landscape of health science.